INTERVENTION 1:	Intervention	0
Treatment (Cabergoline)	Intervention	1
cabergoline	CHEBI:3286	11-22
Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.	Intervention	2
cabergoline	CHEBI:3286	17-28
disease	DOID:4,OGMS:0000031	114-121
cabergoline: Given orally	Intervention	3
cabergoline	CHEBI:3286	0-11
Inclusion Criteria:	Eligibility	0
Patients must have histologically confirmed metastatic breast cancer; tissue (a minimum of 3 slides) from the most recent biopsy is required for review and confirmation of eligibility; NOTE: material should ideally be from the metastatic disease, however material from the primary tumor is acceptable if that is all that is available	Eligibility	1
breast cancer	DOID:1612	55-68
tissue	UBERON:0000479	70-76
disease	DOID:4,OGMS:0000031	238-245
Patients must have stage IV breast cancer	Eligibility	2
breast cancer	DOID:1612	28-41
Patients must have tumors (primary or metastatic) that stain positively for the prolactin receptor	Eligibility	3
prolactin	CHEBI:81580,GO:0005148	80-89
receptor	BAO:0000281	90-98
Patients may have measurable or evaluable disease	Eligibility	4
disease	DOID:4,OGMS:0000031	42-49
Measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral CT scan	Eligibility	5
disease	DOID:4,OGMS:0000031	11-18
diameter	PATO:0001334	120-128
ct	BAO:0002125	211-213
Evaluable disease is disease that does not meet the criteria for measurable disease; examples would include patients with effusions or bone-only disease	Eligibility	6
disease	DOID:4,OGMS:0000031	10-17
disease	DOID:4,OGMS:0000031	21-28
disease	DOID:4,OGMS:0000031	76-83
disease	DOID:4,OGMS:0000031	145-152
Women of childbearing potential must commit to the use of effective barrier (non-hormonal) contraception while on study	Eligibility	7
Patients must have a life expectancy of greater than 12 weeks	Eligibility	8
Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status =< 2	Eligibility	9
group	CHEBI:24433	51-56
Patients may have had a prior diagnosis of cancer if it has been > 5 years since their last treatment	Eligibility	10
cancer	DOID:162	43-49
Leukocytes >= 3,000/uL (microliter)	Eligibility	11
Absolute neutrophil count >= 1,500/uL	Eligibility	12
Platelets >= 100,000/uL	Eligibility	13
Child Pugh score =< 10	Eligibility	14
Patients must be able to swallow and retain oral medication	Eligibility	15
All patients must have given signed, informed consent prior to registration on study	Eligibility	16
Exclusion Criteria:	Eligibility	17
Women who are pregnant or lactating are not eligible for study treatment	Eligibility	18
Patients who are undergoing concomitant radiotherapy are NOT eligible for participation	Eligibility	19
radiotherapy	OAE:0000235	40-52
Patients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a 2 week washout period prior to registration	Eligibility	20
week	UO:0000034	177-181
Patients who are taking any herbal (alternative) medicines are NOT eligible for participation; patients must be off any such medications by the time of registration	Eligibility	21
time	PATO:0000165	144-148
Patients who are receiving concomitant D2-antagonists (such as phenothiazines, butyrophenones, thioxanthenes, or metoclopramide) are NOT eligible for participation; patients must be off any such medications by the time of registration	Eligibility	22
phenothiazines	CHEBI:38093	63-77
thioxanthenes	CHEBI:50930	95-108
metoclopramide	CHEBI:107736	113-127
time	PATO:0000165	214-218
Patients with known brain metastases are NOT eligible for participation	Eligibility	23
brain	UBERON:0000955	20-25
Patients with any of the following conditions or complications are NOT eligible for participation:	Eligibility	24
Uncontrolled hypertension	Eligibility	25
hypertension	HP:0000822,DOID:10763	13-25
Known hypersensitivity to ergot derivatives	Eligibility	26
hypersensitivity	GO:0002524,DOID:1205	6-22
History of cardiac valvular disorders, as suggested by anatomical evidence of valvulopathy of any valve (to be determined by pre-treatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis)	Eligibility	27
history	BFO:0000182	0-7
valve	UBERON:0003978	98-103
valve	UBERON:0003978	195-200
valve	UBERON:0003978	221-226
valve	UBERON:0003978	249-254
mixed	BAO:0002107	243-248
History of pulmonary, pericardial, cardiac valvular, or retroperitoneal fibrotic disorders	Eligibility	28
history	BFO:0000182	0-7
Gastrointestinal (GI) tract disease resulting in an inability to take oral medication	Eligibility	29
disease	DOID:4,OGMS:0000031	28-35
Malabsorption syndrome	Eligibility	30
malabsorption	HP:0002024	0-13
syndrome	DOID:225	14-22
Require intravenous (IV) alimentation	Eligibility	31
History of prior surgical procedures affecting absorption	Eligibility	32
history	BFO:0000182	0-7
Uncontrolled inflammatory GI disease (e.g., Crohn's, ulcerative colitis)	Eligibility	33
disease	DOID:4,OGMS:0000031	29-36
ulcerative colitis	HP:0100279,DOID:8577	53-71
Outcome Measurement:	Results	0
Overall Response Rate (ORR) at 2 Months	Results	1
rate	BAO:0080019	17-21
Overall Response Rate (ORR) is defined as the number of patients that achieved Complete Response (CR) or Partial Response (PR) and will be assessed after 8 weeks (2 cycles) of therapy using CT scan images and RECIST guidelines.	Results	2
rate	BAO:0080019	17-21
ct	BAO:0002125	190-192
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum of LD.	Results	3
target	BAO:0003064	45-51
target	BAO:0003064	151-157
diameter	PATO:0001334	134-142
Progressive Disease (PD): At least a 20% increase in the sum o the LD of target lesions, taking as reference the smallest sum of LD recorded since the treatment started or the appearance of one or more new lesions.	Results	4
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
increase	BAO:0001251	41-49
target	BAO:0003064	73-79
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of LD since the treatment started	Results	5
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
increase	BAO:0001251	83-91
Time frame: After 8 weeks (2 cycles) of treament	Results	6
time	PATO:0000165	0-4
Results 1:	Results	7
Arm/Group Title: Treatment (Cabergoline)	Results	8
cabergoline	CHEBI:3286	28-39
Arm/Group Description: Patients receive cabergoline oral (PO) twice weekly for weeks 1-4. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.	Results	9
cabergoline	CHEBI:3286	40-51
disease	DOID:4,OGMS:0000031	137-144
cabergoline: Given orally	Results	10
cabergoline	CHEBI:3286	0-11
Overall Number of Participants Analyzed: 18	Results	11
Measure Type: Count of Participants	Results	12
Unit of Measure: Participants  0   0.0%	Results	13
Adverse Events 1:	Adverse Events	0
Total: 4/20 (20.00%)	Adverse Events	1
Death NOS 1/20 (5.00%)	Adverse Events	2
death	OAE:0000632	0-5
Pain 1/20 (5.00%)	Adverse Events	3
pain	HP:0012531	0-4
Dyspnea 2/20 (10.00%)	Adverse Events	4
dyspnea	HP:0002094	0-7
